• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

VLA Removal from Official List at close 21/06/201821/06/18 download Created with Sketch. 223.86KB
VLA Implementation of Scheme of Arrangement20/06/18 download Created with Sketch. 89.64KB
VLA Suspension from Official Quotation at close 05/06/18PRICE SENSITIVE05/06/18 download Created with Sketch. 227.31KB
VLA Lodgement of court orders with ASIC05/06/18 download Created with Sketch. 536.97KB
VLA Correction to Scheme of Arrangement Timetable04/06/18 download Created with Sketch. 89.03KB
VLA Federal Court of Australia approves scheme of arrangementPRICE SENSITIVE04/06/18 download Created with Sketch. 92.36KB
VLA VLA Shareholders Vote in Favour of Scheme of ArrangementPRICE SENSITIVE28/05/18 download Created with Sketch. 98.56KB
VLA Shareholder Meeting Scheme of Arrangement Presentation28/05/18 download Created with Sketch. 626.92KB
VLA Shareholder Meeting Scheme of Arrangement Chairman's Address28/05/18 download Created with Sketch. 95.26KB
VLA Update on Scheme of ArrangementPRICE SENSITIVE23/05/18 download Created with Sketch. 55.8KB
VLA Appendix 4C - quarterlyPRICE SENSITIVE24/04/18
VLA Court approves convening of scheme meetingPRICE SENSITIVE20/04/18
VLA New CAVATAK Data at International Oncolytic Virus ConferencePRICE SENSITIVE11/04/18
VLA Ceasing to be a substantial holder from MUFG09/03/18
VLA Ceasing to be a substantial holder from MS08/03/18
VLA Ceasing to be a substantial holder06/03/18
VLA Becoming a substantial holder from MUFG05/03/18
VLA Becoming a substantial holder from MS02/03/18
VLA Ceasing to be a substantial holder02/03/18
VLA Appendix 4D Half Yearly Report and AccountsPRICE SENSITIVE26/02/18
VLA MSD and Viralytics Announce Acquisition AgreementPRICE SENSITIVE21/02/18
VLA Appendix 4C - quarterlyPRICE SENSITIVE24/01/18
VLA Ceasing to be a substantial holder15/01/18
VLA Change of Director's Interest Notice12/01/18
VLA Ceasing to be a substantial holder12/01/18
VLA Appendix 3B10/01/18
VLA Notice of Initial Subsubstantial Shareholder09/01/18
VLA JP Morgan Healthcare conference, new investor presentation08/01/18
VLA Viralytics Receives $6.4 Million R&D Tax IncentivePRICE SENSITIVE08/01/18
VLA Cleansing Notice05/01/18
VLA Appendix 3B05/01/18
VLA $29.6m Equity Placement to Lepu Medical Group of ChinaPRICE SENSITIVE05/01/18
VLA Trading HaltPRICE SENSITIVE04/01/18
VLA Change of Director's Interest Notice x 415/12/17
VLA Ceasing to be a substantial holder14/12/17
VLA Appendix 3B - Issue of Options and Performance Rights12/12/17
VLA Change of Director's Interest Notice06/12/17
VLA Ceasing to be a substantial holder from MUFG04/12/17
VLA Change in substantial holding04/12/17
VLA Ceasing to be a substantial holder from MS04/12/17
VLA Becoming a substantial holder from MUFG01/12/17
VLA Becoming a substantial holder from MS01/12/17
VLA Chairman's Letter to Shareholders28/11/17
VLA Results of Meeting22/11/17
VLA AGM Presentation22/11/17
VLA Chairman's Address to Shareholders22/11/17
VLA New Data at SITC Meeting. Further Studies AnnouncedPRICE SENSITIVE13/11/17
VLA Change of Director's Interest Notice01/11/17
VLA Cleansing Notice31/10/17
VLA Appendix 3B31/10/17
VLA Viralytics to Present at 2017 SITC Annual Meeting31/10/17
VLA Appendix 4C - quarterlyPRICE SENSITIVE25/10/17
VLA Notice of Annual General Meeting/Proxy Form23/10/17
VLA Annual Report to shareholders23/10/17
VLA Date of Annual General Meeting20/09/17
VLA Appendix 3B15/09/17
VLA Viralytics Annual Report and Full Year Financial Results18/08/17
VLA Appendix 4G and Corporate Governance Statement18/08/17
VLA Appendix 4E and Full Year Statutory AccountsPRICE SENSITIVE18/08/17
VLA Becoming a substantial holder07/08/17
VLA Change in substantial holding02/08/17
VLA Change in substantial holding02/08/17
VLA Change in substantial holding27/07/17
VLA Appendix 4C - quarterlyPRICE SENSITIVE18/07/17
VLA Becoming a substantial holder18/07/17
VLA Bio-Marker Data from CANON Bladder Cancer Study Presented26/06/17
VLA Change in substantial holding13/06/17
VLA Update on MITCI and KEYNOTE 200 trials at ASCO Ann MeetingPRICE SENSITIVE06/06/17
VLA Change in substantial holding23/05/17
VLA Ceasing to be a substantial holder22/05/17
VLA Change of Director's Interest Notice05/05/17
VLA Appendix 3B05/05/17
VLA Appendix 3B18/04/17
VLA Appendix 4C - quarterlyPRICE SENSITIVE11/04/17
VLA Progress Report on KEYNOTE 200 at AACR PodiumPRICE SENSITIVE05/04/17
VLA Promising Results MITCI Melanoma Trial at AACR PodiumPRICE SENSITIVE05/04/17
VLA Promising Results CAPRA Melanoma Trial expand to 50 patientsPRICE SENSITIVE04/04/17
VLA Invitation to Conference Call - MITCI Trial Update30/03/17
VLA Becoming a substantial holder06/03/17
VLA Viralytics to Present New CAVATAK Clinical Data at AACRPRICE SENSITIVE02/03/17
VLA Appendix 4D Half Yearly Report and AccountsPRICE SENSITIVE22/02/17
VLA Viralytics Receives $4.3 Million R&D Tax IncentivePRICE SENSITIVE13/02/17
VLA Appendix 4C - quarterlyPRICE SENSITIVE27/01/17
VLA Becoming a substantial holder06/12/16
VLA Change of Director's Interest Notice05/12/16
VLA Change of Director's Interest Notice24/11/16
VLA Change of Director's Interest Notice x 323/11/16
VLA Appendix 3B23/11/16
VLA Results of Meeting23/11/16
VLA AGM Presentation23/11/16
VLA Chairman's Address to Shareholders23/11/16
VLA Viralytics Announces Formation of Clinical Advisory Board22/11/16
VLA Change in substantial holding18/11/16
VLA Change of Directors Interest Notice16/11/16
VLA Promising Advanced Melanoma Results - KEYTRUDA CombinationPRICE SENSITIVE14/11/16
VLA Appendix 4C - quarterly-VLA.AX PRICE SENSITIVE26/10/16
VLA Notice of Annual General Meeting/Proxy Form-VLA.AX 21/10/16
VLA CAVATAK YERVOY Promising Results in Advanced Melanoma - ESMO-VLA.AX PRICE SENSITIVE10/10/16
VLA VLA update on CAVATAK KEYTRUDA Combination trials - ESMO-VLA.AX PRICE SENSITIVE10/10/16
VLA VLA presents at Oncolytic Virus Therapeutics Conference-VLA.AX PRICE SENSITIVE04/10/16
VLA Removal from Official List at close 21/06/2018
21/06/18 download Created with Sketch. 223.86KB
VLA Implementation of Scheme of Arrangement
20/06/18 download Created with Sketch. 89.64KB
VLA Suspension from Official Quotation at close 05/06/18
05/06/18PRICE SENSITIVE download Created with Sketch. 227.31KB
VLA Lodgement of court orders with ASIC
05/06/18 download Created with Sketch. 536.97KB
VLA Correction to Scheme of Arrangement Timetable
04/06/18 download Created with Sketch. 89.03KB
VLA Federal Court of Australia approves scheme of arrangement
04/06/18PRICE SENSITIVE download Created with Sketch. 92.36KB
VLA VLA Shareholders Vote in Favour of Scheme of Arrangement
28/05/18PRICE SENSITIVE download Created with Sketch. 98.56KB
VLA Shareholder Meeting Scheme of Arrangement Presentation
28/05/18 download Created with Sketch. 626.92KB
VLA Shareholder Meeting Scheme of Arrangement Chairman's Address
28/05/18 download Created with Sketch. 95.26KB
VLA Update on Scheme of Arrangement
23/05/18PRICE SENSITIVE download Created with Sketch. 55.8KB
VLA Appendix 4C - quarterly
24/04/18PRICE SENSITIVE
VLA Court approves convening of scheme meeting
20/04/18PRICE SENSITIVE
VLA New CAVATAK Data at International Oncolytic Virus Conference
11/04/18PRICE SENSITIVE
VLA Ceasing to be a substantial holder from MUFG
09/03/18
VLA Ceasing to be a substantial holder from MS
08/03/18
VLA Ceasing to be a substantial holder
06/03/18
VLA Becoming a substantial holder from MUFG
05/03/18
VLA Becoming a substantial holder from MS
02/03/18
VLA Ceasing to be a substantial holder
02/03/18
VLA Appendix 4D Half Yearly Report and Accounts
26/02/18PRICE SENSITIVE
VLA MSD and Viralytics Announce Acquisition Agreement
21/02/18PRICE SENSITIVE
VLA Appendix 4C - quarterly
24/01/18PRICE SENSITIVE
VLA Ceasing to be a substantial holder
15/01/18
VLA Change of Director's Interest Notice
12/01/18
VLA Ceasing to be a substantial holder
12/01/18
VLA Appendix 3B
10/01/18
VLA Notice of Initial Subsubstantial Shareholder
09/01/18
VLA JP Morgan Healthcare conference, new investor presentation
08/01/18
VLA Viralytics Receives $6.4 Million R&D Tax Incentive
08/01/18PRICE SENSITIVE
VLA Cleansing Notice
05/01/18
VLA Appendix 3B
05/01/18
VLA $29.6m Equity Placement to Lepu Medical Group of China
05/01/18PRICE SENSITIVE
VLA Trading Halt
04/01/18PRICE SENSITIVE
VLA Change of Director's Interest Notice x 4
15/12/17
VLA Ceasing to be a substantial holder
14/12/17
VLA Appendix 3B - Issue of Options and Performance Rights
12/12/17
VLA Change of Director's Interest Notice
06/12/17
VLA Ceasing to be a substantial holder from MUFG
04/12/17
VLA Change in substantial holding
04/12/17
VLA Ceasing to be a substantial holder from MS
04/12/17
VLA Becoming a substantial holder from MUFG
01/12/17
VLA Becoming a substantial holder from MS
01/12/17
VLA Chairman's Letter to Shareholders
28/11/17
VLA Results of Meeting
22/11/17
VLA AGM Presentation
22/11/17
VLA Chairman's Address to Shareholders
22/11/17
VLA New Data at SITC Meeting. Further Studies Announced
13/11/17PRICE SENSITIVE
VLA Change of Director's Interest Notice
01/11/17
VLA Cleansing Notice
31/10/17
VLA Appendix 3B
31/10/17
VLA Viralytics to Present at 2017 SITC Annual Meeting
31/10/17
VLA Appendix 4C - quarterly
25/10/17PRICE SENSITIVE
VLA Notice of Annual General Meeting/Proxy Form
23/10/17
VLA Annual Report to shareholders
23/10/17
VLA Date of Annual General Meeting
20/09/17
VLA Appendix 3B
15/09/17
VLA Viralytics Annual Report and Full Year Financial Results
18/08/17
VLA Appendix 4G and Corporate Governance Statement
18/08/17
VLA Appendix 4E and Full Year Statutory Accounts
18/08/17PRICE SENSITIVE
VLA Becoming a substantial holder
07/08/17
VLA Change in substantial holding
02/08/17
VLA Change in substantial holding
02/08/17
VLA Change in substantial holding
27/07/17
VLA Appendix 4C - quarterly
18/07/17PRICE SENSITIVE
VLA Becoming a substantial holder
18/07/17
VLA Bio-Marker Data from CANON Bladder Cancer Study Presented
26/06/17
VLA Change in substantial holding
13/06/17
VLA Update on MITCI and KEYNOTE 200 trials at ASCO Ann Meeting
06/06/17PRICE SENSITIVE
VLA Change in substantial holding
23/05/17
VLA Ceasing to be a substantial holder
22/05/17
VLA Change of Director's Interest Notice
05/05/17
VLA Appendix 3B
05/05/17
VLA Appendix 3B
18/04/17
VLA Appendix 4C - quarterly
11/04/17PRICE SENSITIVE
VLA Progress Report on KEYNOTE 200 at AACR Podium
05/04/17PRICE SENSITIVE
VLA Promising Results MITCI Melanoma Trial at AACR Podium
05/04/17PRICE SENSITIVE
VLA Promising Results CAPRA Melanoma Trial expand to 50 patients
04/04/17PRICE SENSITIVE
VLA Invitation to Conference Call - MITCI Trial Update
30/03/17
VLA Becoming a substantial holder
06/03/17
VLA Viralytics to Present New CAVATAK Clinical Data at AACR
02/03/17PRICE SENSITIVE
VLA Appendix 4D Half Yearly Report and Accounts
22/02/17PRICE SENSITIVE
VLA Viralytics Receives $4.3 Million R&D Tax Incentive
13/02/17PRICE SENSITIVE
VLA Appendix 4C - quarterly
27/01/17PRICE SENSITIVE
VLA Becoming a substantial holder
06/12/16
VLA Change of Director's Interest Notice
05/12/16
VLA Change of Director's Interest Notice
24/11/16
VLA Change of Director's Interest Notice x 3
23/11/16
VLA Appendix 3B
23/11/16
VLA Results of Meeting
23/11/16
VLA AGM Presentation
23/11/16
VLA Chairman's Address to Shareholders
23/11/16
VLA Viralytics Announces Formation of Clinical Advisory Board
22/11/16
VLA Change in substantial holding
18/11/16
VLA Change of Directors Interest Notice
16/11/16
VLA Promising Advanced Melanoma Results - KEYTRUDA Combination
14/11/16PRICE SENSITIVE
VLA Appendix 4C - quarterly-VLA.AX
26/10/16PRICE SENSITIVE
VLA Notice of Annual General Meeting/Proxy Form-VLA.AX
21/10/16
VLA CAVATAK YERVOY Promising Results in Advanced Melanoma - ESMO-VLA.AX
10/10/16PRICE SENSITIVE
VLA VLA update on CAVATAK KEYTRUDA Combination trials - ESMO-VLA.AX
10/10/16PRICE SENSITIVE
VLA VLA presents at Oncolytic Virus Therapeutics Conference-VLA.AX
04/10/16PRICE SENSITIVE
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.